Ozempic And GLP-1 Drugs: From Unexpected Changes In Brain Connectivity In Adolescents To Dopamine Dampening In The Nucleus Accumbens, A 50-56% Lower Risk Of Alcohol Use Disorder, And Activation Of The Central Amygdala. The Weight-Loss Drug Is Rewriting What We Thought We Knew About Appetite, Addiction, And The Brain
According to Yahoo News, citing a Washington Post investigation by Ariana Eunjung Cha, scientists are discovering that GLP-1 drugs; the class that includes semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound are affecting the brain in ways that go far beyond appetite suppression.
Tens of millions of people are now taking these medications worldwide, turning what began as an obesity and diabetes treatment into what could be modern medicine’s largest unplanned neuroscience experiment.
The implications are profound and still poorly understood. The research is preliminary. The findings are, in the words of one of the scientists conducting them, both “very exciting” and not fully explained. What is no longer deniable is the pattern.
The dopamine mechanism and why it matters for addiction. GLP-1 receptors are distributed widely across the brain, including in regions that govern the reward circuit: the mesolimbic dopamine system. When semaglutide or tirzepatide binds to those receptors, dopamine release is dampened in the ventral tegmental area, reward is uncoupled from the stimulus in the nucleus accumbens, top-down control is restored in the prefrontal cortex, and there is early evidence of increased neuronal plasticity in the hippocampus.
The reward circuit is, at its simplest, the brain’s system for assigning importance and pleasure to stimuli and repeating those behaviours. Dopamine is the chemical that fires the signal. Scientists suspect GLP-1 drugs may dampen the brain’s dopamine-driven reward systems that determine what feels pleasurable and worth repeating which could lessen the urges associated with addiction.
They are also investigating whether the drugs affect the amygdala, which helps regulate fear, stress, and emotional processing.
The unexpected findings in brain connectivity. One of the most striking and least expected findings comes from the University of Colorado Anschutz. In a study of adolescents and young women with a hormonal ovarian condition, researchers reviewed brain scans taken before and after GLP-1 drug use and found notable changes in brain connectivity.
Assistant professor Allison Shapiro said: “We didn’t expect to see this effect, and we really don’t know what it means.” The changes appeared in the salience network; the system the brain uses to determine what deserves attention and what can be safely ignored. The salience network sits upstream of the reward system. It is the brain’s relevance filter.
If GLP-1 drugs are altering how the salience network operates, the downstream effects on craving, attention, motivation, and emotional processing could be significant and wide-ranging.
The oral small-molecule pathway: a deeper penetration than expected. A separate NIH-funded study published in recent weeks has added another layer of surprise. Researchers found that oral small-molecule GLP-1 drugs activate the central amygdala; a brain region tied to desire and reward that scientists previously did not believe GLP-1 drugs could directly access reducing dopamine release during pleasure-driven eating.
The finding matters for two reasons. First, it establishes that the neurological effects of GLP-1 drugs reach deeper into the brain than earlier models predicted. Second, it opens the question of whether newer oral formulations; orforglipron and danuglipron, currently in trials could be used to target addiction-related craving circuits that injectable semaglutide cannot reach as directly.
As co-corresponding author Ali Guler said: “Now it seems oral small-molecule GLP-1s also dial back eating for pleasure by engaging a brain reward circuit.”
The addiction evidence is accumulating rapidly. A 2024 Nature Communications study found that those prescribed semaglutide had a 50% to 56% lower risk of developing or relapsing into alcohol use disorder compared with those who took other anti-obesity medications.
A January 2026 systematic review from the Mayo Clinic in Frontiers in Pharmacology confirmed the breadth of this signal across alcohol, nicotine, cocaine, and opioid models in both preclinical and clinical settings.
Eli Lilly has launched a large clinical trial examining whether tirzepatide could help treat alcohol use disorder, expected to conclude by the end of this year or early 2027.
Several major studies examining GLP-1 drugs on nicotine dependence, opioid and cocaine use disorders, gambling addiction, and binge eating are also underway.
Users themselves have been reporting these effects anecdotally for years. People on Ozempic describe a “mental quiet”; a reduction in the constant background noise of craving. Not just for food, but for alcohol, cigarettes, and compulsive online shopping.
For many users, the effect was unexpected and not mentioned by their prescribing physician. The clinical trials now underway are attempting to quantify what patients have been describing informally since the drugs reached mass adoption.
The other side of the neurological ledger. The brain changes are not uniformly positive. Side effects reported include brain fog, emotional flattening, and reduced motivation. Dampening the dopamine reward system does not discriminate between maladaptive cravings for alcohol, cigarettes, compulsive eating and adaptive pleasures.
If the reward system is broadly quieted, the suppression of addiction-related craving may come at the cost of reduced motivation for productive activity, diminished pleasure from social connection, or emotional blunting.
Lorenzo Leggio of the National Institute on Drug Abuse, whose team uses simulated bars and virtual reality to study how GLP-1 drugs affect craving responses, captured the ambivalence of the field in one sentence: “It’s very exciting times, but we don’t fully understand how it works.”
The scale of the experiment is historically unprecedented. Every new drug that reaches widespread adoption affects the people who take it. But the speed and scale at which GLP-1 drugs have diffused through the global population; tens of millions of people within a few years, with projections suggesting hundreds of millions over the next decade means that the neurological reprogramming described in the current research is already happening at population scale, years before the clinical trials needed to understand it have been completed.
This research is part of a larger scientific shift away from treating brain and physical health as separate domains. The brain is metabolic tissue. The hormones that regulate appetite and blood sugar also regulate mood, motivation, fear, and reward.
The finding that drugs designed to mimic those hormones reach deep into the reward and emotional circuitry of the brain is not a side-effect surprise. It is a confirmation that the brain and the body were always one system and that medicine is only now beginning to treat them as such.
The verdict. Ozempic began as a diabetes drug. It became a weight-loss phenomenon. It may be in the process of becoming something else entirely; a neurological intervention whose full effects, both therapeutic and adverse, are being discovered in the world rather than in the clinic.
The addiction trials underway will produce the first rigorous evidence within the next twelve to eighteen months. Until then, the tens of millions of people currently taking GLP-1 drugs are not just patients. They are, whether they know it or not, the participants in the largest unplanned neuroscience experiment in the history of medicine.
To check out our previous coverage on healthcare, pharmacology, and neuroscience, read our articles here.
